mdi-book-open-variant Impressum mdi-help Hilfe / Anleitung mdi-printer Webseite ausdrucken mdi-bookmark Bookmark der Webseite speichern mdi-magnify Suche & Index Wirkstoffe mdi-sitemap Sitemap CliniPharm/CliniTox-Webserver mdi-home Startseite CliniPharm/CliniTox-Webserver mdi-email Beratungsdienst: Email / Post / Fax / Telefon

Ikai Y, Oka H, Hayakawa J, Matsumoto M, Saito M et al
Total structures and antimicrobial activity of bacitracin minor components.

Jpn J Antibiot, 48(3): 233-242, 1995
ISSN: 0368-2781 The Japanese Journal of Antibiotics (PubMed)

Abstract
Total structures of 13 minor components of bacitracin (BC) were proposed, and their antimicrobial activities were investigated. The components of BC including bacitracins A (BC-A) and F (BC-F) were isolated by preparative HPLC and were hydrolyzed under acidic conditions. The resulting amino aids were derivatized with 1-fluoro-2,4-dinitrophenyl-5-L-alanineamide and were separated by HPLC to determine their absolute configurations. It was found that the N-terminal amino acids of BC-A and its related components were epimerized during the hydrolysis to yield their enantiomers. The formation of these artifactual amino acids suggests that our previously proposed structures of the BC minor components are incorrect; therefore, the structures were corrected based on these results. The structures of the BC minor components were the same as that of BCs-A and -F except that one to three of the L-isoleucines, including the N-terminal one, were replaced by L-valines. These structures were confirmed by tandem mass spectrometry under fast atom bombardment (FAB) conditions and Frit-FAB liquid chromatography/mass spectrometry. Based on the UV spectra of the BC components determined by photodiode array detection-HPLC analysis, a new systematic nonmenclature was proposed for the minor components. The isolated components were also used for the determination of their minimal inhibition concentrations and it was found that BC-A is 2 approximately 8 times more potent than the other minor components against strains of Micrococcus luteus and Staphylococcus aureus.

© 2021 - Institut für Veterinärpharmakologie und ‑toxikologie

Es kann keinerlei Haftung für Ansprüche übernommen werden, die aus dieser Webseite erwachsen könnten.